Barreras y estrategias para optimizar el uso de AR GLP-1 en pacientes con diabetes tipo 2 y alto riesgo cardiovascular o enfermedad cardiovascular establecida: Consenso Delphi

Consensus on barriers and strategies for optimal clinical practice use of GLP-1 RAs in patients with type 2 diabetes and high cardiovascular risk or established cardiovascular disease.

Authors: Manuel Gargallo Fernández, Manuel Botana López, Miguel Camafort Babkowski, Raquel Campuzano Ruiz, Ana Cebrián Cuenca, Esther Artime Freire, Silvia Díaz-Cerezo, Miriam Rubio de Santos, Raúl Sanchon, Héctor D. de Paz

Year: 2022

Congress: 63 Congreso Nacional de la Sociedad Española de Endocrinología y Nutrición (SEEN). Las Palmas de Gran Canaria. 26- 28 de octubre del 2022

Download PDF

Subscribe to Outcomes´10

Name *

E-mail *

Todos los campos marcados con un * son obligatorios

Responsible for the data: Outcomes'10, s.l.u., Purpose: Sending commercial communications. Legitimation: Art. 6.1 Consent of the interested party. Recipient: No data is transferred unless expressly authorised. You may exercise your rights on data protection (access, rectification, opposition, deletion, automated decisions, limitation of treatment, portability) by email at dpo@outcomes10.com. Data will be retained for the time necessary to fulfill its purpose and derived responsibilities by current regulations and the deadlines in the applicable regulations on archives and documentation. In any case, you can request the protection of the Spanish Data Protection Agency through its website www.aepd.es/. In addition, you can consult more information on the privacy policy

I have read and accepted the privacy policy